| アイテムタイプ |
itemtype_ver1(1) |
| 公開日 |
2024-05-24 |
| タイトル |
|
|
タイトル |
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors |
|
言語 |
en |
| 著者 |
Liang, Yao
Maeda, Osamu
Ando, Yuichi
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
権利情報 |
This is a pre-copyedited, author-produced version of an article accepted for publication in [Japanese Journal of Clinical Oncology] following peer review. The version of record [Yao Liang, Osamu Maeda, Yuichi Ando, Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors, Japanese Journal of Clinical Oncology, Volume 54, Issue 4, April 2024, Pages 365–375, https://doi.org/10.1093/jjco/hyad184] is available online at: https://doi.org/10.1093/jjco/hyad184. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Although immune checkpoint inhibitors have greatly improved cancer therapy, they also cause immune-related adverse events, including a wide range of inflammatory side effects resulting from excessive immune activation. Types of immune-related adverse events are diverse and can occur in almost any organ, with different frequencies and severities. Furthermore, immune-related adverse events may occur within the first few weeks after treatment or even several months after treatment discontinuation. Predictive biomarkers include blood cell counts and cell surface markers, serum proteins, autoantibodies, cytokines/chemokines, germline genetic variations and gene expression profiles, human leukocyte antigen genotype, microRNAs and the gut microbiome. Given the inconsistencies in research results and limited practical utility, there is to date no established biomarker that can be used in routine clinical practice, and additional investigations are essential to demonstrate efficacy and subsequently facilitate integration into routine clinical use. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Oxford University Press |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプresource |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1093/jjco/hyad184 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1465-3621 |
| 書誌情報 |
en : Japanese Journal of Clinical Oncology
巻 54,
号 4,
p. 365-375,
発行日 2024-04
|
| ファイル公開日 |
|
|
日付 |
2024-10-01 |
|
日付タイプ |
Available |
irAE_manuscript_accepted_version.pdf (426 KB)
